UBS Group
SBFM

UBS Group’s Sunshine Biopharma SBFM Stock Holding History

UBS Group’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110
Closed -$1.15K – 10958
2026
Q1 		$1.15K Sell
110
-77
-41% -$908 ﹤0.01% 9607
2025
Q4 		$2.3K Buy
187
+166
+790% +$2.62K ﹤0.01% 9333
2025
Q3 		$307 Hold
21
– – ﹤0.01% 9747
2025
Q2 		$297 Sell
21
-1,968
-99% -$28.8K ﹤0.01% 9885
2025
Q1 		$38K Buy
1,989
+1,902
+2,186% +$47.8K ﹤0.01% 7785
2024
Q4 		$2.6K Buy
+87
New +$2.48K ﹤0.01% 9015
2024
Q3 		– Hold
0
– – – 9992
2024
Q2 		– Hold
0
– – – 10015
2024
Q1 		– Hold
0
– – – 9930
2023
Q4 		– Hold
0
– – – 8578
2023
Q3 		– Hold
0
– – – 9897
2023
Q2 		– Hold
0
– – – 9543
2023
Q1 		– Hold
0
– – – 8655
2022
Q4 		– Hold
0
– – – 9307
2022
Q3 		– Hold
0
– – – 10846
2022
Q2 		– Hold
0
– – – 10855
2022
Q1 		– Hold
0
– – – 8991

Other funds holding SBFM

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SFG
Strive Financial Group Carmel, Indiana $230M AUM
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS Group's SBFM Position: Q2 2026 in Review

UBS Group sold out of Sunshine Biopharma (SBFM) in Q2 2026, closing a stake of 110 shares — an estimated $1.15K sold.

UBS Group first reported a position in SBFM in Q4 2024 and held it in 6 quarters. The position peaked at $38K in Q1 2025. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

  • UBS Group reported no remaining Sunshine Biopharma position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 110 Sunshine Biopharma shares in Q2 2026, an estimated $1.15K.
  • UBS Group first reported a position in Sunshine Biopharma in Q4 2024 and held it in 6 quarters.
  • UBS Group's Sunshine Biopharma position peaked at $38K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.